• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Gilead Sciences - Articles and news items

ebola

PREVAIL IV – a trial to investigate if GS-5734 eliminates Ebola virus from semen

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

The six-month study will enrol 60 to 120 Ebola survivors whose semen has evidence of Ebola virus RNA prior to their enrolment…

epclusa

FDA approves Epclusa for treatment of chronic HCV

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection…

odefsey

EC grants marketing authorisation to Odefsey in HIV

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients…

Epclusa

Positive CHMP opinion for Gilead’s Epclusa in HCV

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The EMA’s CHMP has adopted a positive opinion on Gilead’s Epclusa for the treatment of chronic hepatitis C virus…

descovy

EC grants marketing authorisation for two doses of Gilead’s Descovy

Industry news / 25 April 2016 / Victoria White, Digital Content Producer

Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients…

hbv

Gilead announces results from two Phase III studies of TAF in HBV

Industry news / 15 April 2016 / Victoria White, Digital Content Producer

Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection…

zydelig

EMA to review Gilead’s Zydelig over safety concerns

Industry news / 14 March 2016 / Victoria White

The European Medicines Agency’s review follows concerns over serious adverse events in ongoing clinical trials of Zydelig (idelalisib)…

descovy

CHMP adopts positive opinion of Gilead’s Descovy

Industry news / 26 February 2016 / Victoria White

Descovy is an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents in combination with other HIV antiretroviral agents…

hepatitis B

Gilead’s MAA for TAF in hepatitis B now under assessment by the EMA

Industry news / 26 February 2016 / Victoria White

TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread at one-tenth of the dose…

hiv-1

Gilead announces results from study evaluating switching to F/TAF-based regimens from Truvada

Industry news / 24 February 2016 / Victoria White

At Week 48 of the study, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens in HIV-1 infected adult patients…

Truvada for PrEP

EMA validates Gilead’s Type II variation application for Truvada for PrEP

Industry news / 1 February 2016 / Victoria White

The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP…

taf

Gilead’s TAF meets primary objectives in two Phase 3 HBV trials

Industry news / 6 January 2016 / Victoria White

The studies demonstrated that TAF was non-inferior to Gilead’s Viread (tenofovir disoproxil fumarate, TDF) based on the percentage of patients with HBV DNA levels below 29 IU/mL at 48 weeks of therapy…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +